DT05 Rec'd PCT/PT0

oved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information vales it contains a valid OMB control number.

Attorney Docket Number

Substitute for form 1449/PTO

C	if Known			
Application Number	Not Yot.Known-10/518,003			
Filing Date	Herewith			
First Named Inventor	Daniel S. MARTIN			
Art Unit	Not Yet Known 1623			
Examiner Name	Not Yet Known			

1636-C-PCT-US

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Sheet 1

			U. S. PATENT DO	OCUMENTS		
Examiner Cit Initials* No		Document Number  Number-Kind Code <sup>2 (V known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, When Relevant Passages or Relevar Figures Appear	
	<del></del>	US-			T iguico reposit	
	<b></b>	US-	+			
	<u> </u>	US-				
1		US-				
		US-			<u> </u>	
		US-				
		US-				
T		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
<b> </b>		US-				
		US-				
		US-		- A		
		US-				
		US-				

<u> </u>		FORE	IGN PATENT DOCU	MENTS		
Liter ine Initials*	Cite No.1	Foreign Patent Document Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>3</sup> (# known)	MM-DD-YYYY		Or Relevant Figures Appear	TS
Me	15	PCT/US01/46886	12-04-2001	Shan-Kettering Inethits for Canour Research, et al.	PCT International Search Report	
7	16	PCT/US01/46886	12-04-2001	Steen-Kettering Institute for Corner Research, et al.	PCT Written Opinion	
<u> </u>	17	PCT/US01/46886	12-04-2001	Sixon-Ketteding Institute for Cercer Rasserch, et al.	PCT International Preliminary Examination	<u> </u>
	18	PCT/US03/18716	06-13-2003	Sion-Kettering Institute for Cencer	PCT Notification of Transmittal of the	
ME	~ 30	PCT/US03/18716	06-13-2003	Stean-Kettering Institute for Cencer Research, et al.	PCT International Search Report	П
**	- 57	WO 93/23014-A1		Sitem-Kettering institute for Cancer Research,	PCT Published Application	

Examine L. El Crane Date 09/29/2005 Signature Considered con

\*EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

\*\* Duplicate citation: see PTO-892 for original citation.

705 Rec'd : CT/PTO 1 0 DEC 2000 PTO/SB/08B (02-03) oved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act 67-7895, no persons are required to respond to a collection of information valess it contains a valid OMB control number.

Substitute for form 1449/PTO					Complete
				Application Number	Not Yet Known 10/518,003
			CLOSURE	Filing Date	Herewith
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Daniel S. MARTIN
	(Use as many she	ote se n	ocaccind	Art Unit ·	Not Yet Known 1623
- lose as many sheets as necessary)			· ·	Examiner Name	Not Yet Known
Sheet	2	of	7	Attorney Docket Number	636-C-PCT-US

	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Herceg Z. & ZQ. Wang. Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis. Mol. Cell Biol. 19:5124-5133 (1999)		
Hirsch, T. et al. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene 15:1573-1581 (1997)		•
3	Geschwind, JF. H., et al. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Canc. Res. 62:3909-3913 (2002) (07/15/02)	
4	Green, D.R. & Reed, J.C. Mitochondria & apoptosis. Science 281:1309-1312 (1998)	•
5	Leist, M. et al. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. 185:1481-1486 (1997)	
6	Lemaire, et al. Inhibition of caspase activity induces a switch from apoptosis to necrosis. FEBS Lett. 425:266-270 (1998)	
7	Martin, D.S., et al. ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach. Canc. Res. 60:6776-6783 (2000)	
8	Mehmet, H., et al. Relation of impaired energy metabolism to apoptosis and necrosis following transient cerebral hypoxia-ischaemia. Cell Death Differ. 5:321-329 (1998)	
9	Nicotera, P. & Leist, M. Energy supply and the shape of death in neurons and lymphoid cells. Cell Death Differ. 4:435-442 (1997)	
10	Nieminen, AL., et al. ATP depletion rather than mitochondrial depolarization mediates hepatocyte killing after metabolic inhibition, J. Am. Phys. 267:C67-C74 (1994)	
	No. <sup>1</sup> 1 2 3 4 5 6 7 8	No. the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.  Herceg Z. & ZQ. Wang. Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis. Mol. Cell Biol. 19:5124-5133 (1999)  Hirsch, T. et al. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene 15:1573-1581 (1997)  Geschwind, JF. H., et al. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Canc. Res. 62:3909-3913 (2002) (07/15/02)  Green, D.R. & Reed, J.C. Mitochondria & apoptosis. Science 281:1309-1312 (1998)  Leist, M. et al. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. 185:1481-1486 (1997)  Lemaire, et al. Inhibition of caspase activity induces a switch from apoptosis to necrosis. FEBS Lett. 425:266-270 (1998)  Martin, D.S., et al. ATP repletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach. Canc. Res. 60:6776-6783 (2000)  Mehrnet, H., et al. Relation of impaired energy metabolism to apoptosis and necrosis following transient cerebral hypoxia-ischaemia. Cell Death Differ. 5:321-329 (1998)  Nicotera, P. & Leist, M. Energy supply and the shape of death in neurons and lymphoid cells. Cell Death Differ. 4:435-442 (1997)

		<u> </u>				
Examiner					Date	
Signature	L. E.	Crane	Mr.	have	Considered	09/29/2005
457144444						

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO is to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (02-03) oved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete CAPCT/PTO 1 0 DFC 200
	Application Number	Net Yet Knewn 10/518,003
INFORMATION DISCLOSURE	Filing Date	Herewith
STATEMENT BY APPLICANT	First Named Inventor	Daniel S. MARTIN
(Use as many sheets as necessary)	Art Unit	Not Yot Known 1623
	Examiner Name	Not Yet Known
Sheet 3 of 7	Attorney Docket Number	636-C-PCT-US

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>		
Re	Nord, L.D., et al. Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion. Canc. Chemo. Pharm. 40:376-384 (1997)		
	12	Sane, AT. & Bertrand, R. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death. Canc. Res. 59:3565-3569 (1999)	
	Sweet, S. & Singh, G. Accumulation of human promyelocytic leukemic(HL-60) cells at two energetic cell cycle checkpoints. Canc. Res. 55:5164-5167 (1995)		1.
Ne	Tsujimoto, Y. Apoptosis and necrosis: Intracellular ATP level as a determinant for cell death modes. Cell Deat Differ. 4:429-434 (1997)		
**	19	Coloficro, J.R., Stelfi, R.L., Nord, L.D., Mardin, D.S., Biochemical modulation of tumor cell energy IV. Evidence for the contribution of ATP depletion to chemotherapeutically-induced tumor regression. Biochem. Pharmacol.; 1995, 50(11):1943-1948, 1995.	
Re	20	Hageboutros, A., Judes, G.R., Brennan, J., Green, F., Joffman, J., LaCreta, F.P., Colofiore, J., Martin, D.S., Ozols, R.F., O'Dwyer P.J., Phase I trail of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside. Cancer Chemother. Pharmacol.; 1998, 37(3):229-234.	
	21	Kelsen, D., Martin, D.S., Colofiore, J., Sawyer, R., Colt, D., A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. Cancer; 1992, 70(7): 1988-1992.	,
	Kemeny, N., Schneider, A., Martin D.S., Colofiore J, Sawyer, R.C., Derby, S., Salvia, B., Phase I trial of N-phosphonacetyl-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer. Cancer Res.; 1989, 49(16): 4636-4639.		
	23	Kemeny, N.E., Schneider, A., Martin, D.S., Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity. Cancer Invest.; 1990, 8(2):263-264.	
The	24	Koutcher, J.A., Alfieri, A.A., Matie, C., Meyer, K.L., Street, J.C., Martin, D.S., Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies. Magn. Reson. Med., 1996, 36(6):887-892.	

Examiner Signature	D. E. Crane	Mer Cours -	Date Considered	09/29/2005	
*EXAMINER: In	itial if reference considered whether	of one citation is in conformation with NADED	200 5 11 11	1	

considered. Include copy of this form with next communication to applicant.

considered. Include copy or mis form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

\*\* Duplicate citation: see PTO-892 for original citation.

Rec'd PCT/PTO 1 0 DEC 200

oved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Index the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information usless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete Company Company of the Complete Complete Complete Complete Complete Complete Complete Complete Company of the Complete Complete Complete Complete Complete Complete Complete Company of the Comp
	Application Number	Not Yet Known 10/518,003
INFORMATION DISCLOSURE	Filing Date	Herewith
STATEMENT BY APPLICANT	First Named Inventor	Daniel S. MARTIN
(Use as many sheets as necessary)	Art Unit	Not Yet Known 1623
	Examiner Name	Not Yet Known
Sheet 4 of 7	Attorney Docket Number	636-C-PCT-US

·	, ————————————————————————————————————	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	No. the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
HC	25	Koutcher, J.A., Alfieri, A.A., Tsai, J.C., Matei, C., Stolfi, R.L., Ballon, D., Martin, D.S., Evaluation of chemotherapy and radiation enhancement and 31P NMR spectral changes induced by biochemical modulation. Cancer Invest., 1997, 15(2)111-120.	
**	26	Koutcher, J.A., Alflert, A.A., Thaler, H., Matei, C., Martin, D.S., Radiation enhancement by biochemical modulation and 5-fluorouracil. Int. J. Rad. Oncol.; 1997, 39(5):1145-1152.	
Mc	27	Mahmood, U., Street, J.C., Matei, C., Ballon, D., Martin, D.S., Koutcher J.A., In vivo detection by 31P NMR of pentose phosphate pathway block secondary to biochemical modulation. NMR Biomed.; 1996, 9(3):114-120.	
	28	Martin DS, Kerneny NE. 1992. Modulation of fluorouracij by N-phosphonacetyl-L-aspartate: a review. Semin. Oncol.; 19(2 Suppl 3):49-55. (M4nch, 1992)	•
	29	Martin, D.S., Kemeny, N.E., Overview of N-phosphonacetyl-L-aspartate + fluorouracil in clinical trials. Semin. Oncol.; 1992, 19(2 Suppl 3):228-233./3	19:
Me	30	Martin, D.S, Stoffi, R.L., Coloflore, J.R., Nord, L.D., Sternberg, S., Blochemical modulation of tumor cell energy in vivo: II. A lower dose of Adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed. Cancer Invest.; 1994, 12(3):296-307.	
88	31	Marke, S., Stelfi, R.L., Coloffore, LR., Nord, L.D., Marked enhancement in vivo of paclitaxel (* (**)xol's) tumor-regressing activity by ATP-depleting modulation. Anticancer Drugs; 1996, 7(6)655-659.	
Mic	32	Martin, D.S., Schwartz, G.K., Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade. Oncol. Res.; 1997, 9(1):1-5	
	33	Martin, D.S., Spriggs, D., Koutcher, J.A., A concomitant ATP-depleting strategy markedly enhances anticancer agent activity. Apoptosis; 2001, 6:125-131, 2001.	
Re	34	Martin, D.S. Purine and pyrimidine biochemistry, and some relevant clinical and preclinical cancer chemotherapy research in: G. Powis and R.A. Prough (eds), Metabolism and Action of Anti-Cancer Drugs,91-140. London, Taylor and Francis, 1987.	

Examiner Signature L. E. Crane Date Considered 09/29/2005

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

\*\* Duplicate citation: see PTO-892 for original citation.

DT05 Rec'd PCT/PT0 18 U D 3

U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and Trademark Office; U.S. DEPARTMENT OF COMMERCE and the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete
	Application Number	Not Yot Known 10/518,003
INFORMATION DISCLOSURE	Filing Date	Herewith
STATEMENT BY APPLICANT	First Named Inventor	Daniel S. MARTIN
(Use as many sheets as necessary)	Art Unit	Not Yet Known 1623
(See as many allows as necessary)	Examiner Name	Not Yet Known
Sheet 5 of 7	Attorney Docket Number	636-C-PCT-US

	_	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
M	35	Martin, D.S., Stolfi, R.L., Sawyer, R.C., Spiegelman, S. Casper, E.S. and Young, C.W. Therapeutic utility of utilizing low doses of N-{phosphonacetyl)L-aspartic acid in combination with 5-fluouroucil; a murine study with clinical relevance. Cancer Res. 43:2317-2321, 1983.			
	36	Martin, D.S., Alfieri, A., Koutcher, J.A., et al., Selective-killing of drug-resistant mammary carcinomas by exploiting the tumor cell ATP-viability threshold. Proc. AACR 45:570 (Abstract 2462), 2004.			
	37	Martin, D.S., Stolfi, R.L., Cotofiore, J.C., Koutcher, J.A., Alfieri, A., Sternberg, S., and Nord, L.D. Apoptosis resulting from anti-cancer agent activity in vivo is enhanced by biochemical modulation of turnor cell energy. In: M. Lavin and D. Welters (eds.) Programmed Cell Death. The Cellular and Molecular Biology of Apoptosis 279-296, New York: Harwood Academic 1993.			
	38	Martin, D.S., Stolfi, R.L., Nord, L.D. and Colofiore, J.R. Enhancement of chemotherapeutically-induced apoptosis in vivo by biochemical modulation of poly-(ADP-ribose) polymerase. Oncol. Rep. 3:317-322, 1998.	-		
	39	Martin, D.S Cancer chemotherapy: past is prologue. Mt. Sinai. J. Med. 52:426-434, 1985.	,		
	40	Martin, D.S., Bertino, J.R., and Koutcher, J.A. ATP depletion. + pyrimidine depletion can markedly enhance cancer therapy. Fresh insight for a new approach. Cancer Res. 60:6776-6783, 2000.			
±± (	41	Koutcher, J.A., Alfieri, A., Stolfi, R.L., Devitt, M.L., Coloffore, J.R., Nord, L.D., and Martin, D.S. Potentiation of three drug chemotherapy regimen by radiation. Cancer Res. 53:3518-3823, 1993.			
	42	Colofiore, J.R., Stolfi, R.L., Nord, L.D., and Martin, D.S. On the relationship of ATP-depletion to chemotherapeutically-induced tumor regression. Int. J. Oncol. 7:1401-1404, 1995.			
	43	Nord, L.D. Stolfi, R.L., Coloftore, J.R., Martin, D.S., Correlation of retetniton of tumore methylmercaptopurine riboside-5'-phophate with effectiveness in CD8F1 murine mammary tumor regression. Biochem Pharmacol; 1996, 51(5):621-627.			
Re	44	Nord, L.D., Stolfi, R.L., Alfierl, A.A., Netto, G., Reuter, V., Sternberg, S.S., Colofiore, J.R., Koutcher, J.A., Martin, D.S., Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion. Cancer Chemother. Pharmacol.: 1997, 40:376-384.	<b>***</b> *********************************		
		· · · · · · · · · · · · · · · · · · ·			

Examiner	-	777	0	101	Date	<u> </u>
Signature	L.	E.	Crane	In to leave	Considered	09/29/2005
APT 3 CA A A SA S COM			<del>``</del>			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

oved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Index the Paperwork Reduction Act of 1995: no persons are required to respond to a collection of information and set it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete pown
:	Application Number	Net Yet Known 10/518,003
INFORMATION DISCLOSURE	Filing Date	Herewith
STATEMENT BY APPLICANT	First Named Inventor	Daniel S. MARTIN
(Use as many sheets as necessary)	Art Unit	Not Yet Known 1623
lose of many streets as recessary	Examiner Name	Not Yet Known
Sheet 6 of 7	Attorney Docket Number	636-C-PCT-US

	_	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
the	45	O'Dwyer, P.J., Judes, G.R., Colofiore, J., Walczak, J., Hoffman, J., LaCreta F.P., Comis, R.L., Martin, D.S., Ozols, R.F., Phase I trial of fluroruracil modulation by of N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through blochemical analysis of sequential tumor biopsy specimens. J. Natl. Cancer Inst.; 1991, 83(17):1235-1240.	
ge	46	Stolfi, R.L., Martin, D.S., Enhancement of anticancer activity by selective inhibition of rapidly proliferating tissues of the host. Pharmacol. Ther.; 1991, 49(1-2):43-54.	
**	47	Stelfi, R.L., Gelefiere, J.R., Nerd, L.D., Keutcher, J.A., Martin, D.S., Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination. Cancer Res.; 1992, 52(15):4074-4081.	
Me	48	Stolfi, R.L., Colofiore, J.R., Nord, L.D., Martin, D.S., Enhanced antitumor activity of an Adriamycin + 5-fluorouracil combination when preceded by biochemical modulation. Anticancer Drugs; 1996, 7(1):100-104.	
	49	Jurkowitz, et al., Adenosine, Inosine, and Guanosine Protect Glial Cells During Glucose Deprivation and Mitochondrial Inhibition: Correlation Between Protection and ATP Preservation. Journal of Neurochemistry, 1998, 71(2):535-548.	
	50	Lieberthal, et al., Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. American Physiological Society; 1998, F315-F327.	
	51	Lu, et al., Cellular ATP Depletion by LY309887 as a Predictor of Growth Inhibition in Human Tumor Cellulaes. Clinical Cancer Research; January 1, 2000, 5:271-277.	
. (	52	Venkatachalam, et al., Energy Thresholds That Determine Membrane Integrity and Injury in a Renal Epithelial Cell Line (LLC-PK1). J. Clin. Invest.; 1988, 81:745-758.	88
	53	Anundi, et al., Fructose prevents hypoxic cell death in liver. The American Journal of Physiology; 1987, Sep;253(3 Pt 1):G390-G396.	
Re	54	Cannon, et al., The Effects of Fructose on Adenosine Triphosphate Depletion following Mitochondrial Dysfunction and Lethal Cell Injury in Isolated Rat Hepatocytes. Toxicology and Applied Pharmacology; 1991, 108(3):407-416.	

Examiner Signature L. E. Crane Date Considered 09/29/2005

\*EXAMINER: Initial if reference considered, whether or not distalon is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

\*\* Duplicate citation: see PTO-892 for original citation.

DT05 Rec'd PCT/PTO 170 DEC 200

PTO/SB/08B (02-03) oved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1997, no persons are required to respond to a collection of information as it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete		
Substitute for form 1445/170	Application Number	Not Yet Known 10/518,003	
INFORMATION DISCLOSURE	Filing Date	Herewith	
STATEMENT BY APPLICANT	First Named Inventor	Daniel S. MARTIN	
(Use as many sheets as necessary)	Art Unit	Not Yot Known 1623	
(Ose as many sneets as necessary)	Examiner Name	Not Yet Known	
Sheet 7 : of 7	Attorney Docket Number	636-C-PCT-US	

Examiner Initials*	Cite No.1				
Me	55	Yager, et al., Correlation between Content of High-Energy Phosphates and Phypoxic-Ischemic Damage in Immature and Mature Astrocytes. Elsevier Science Publishers, Amsterdam; 1994, 82(1-2):62-68. (October 14, 1994).			
			•		
			·		
	·				

	<u>.                                  </u>				
Examiner Signature	L. E. Crane	My Cours	Date Considered	09/2 <b>9</b> /2005	
*EYAMINED: I	itial if reference concidend what	has applied altables in in conference with \$400	O COO D	to at the sale of the sale	_

\*EXAMINER: Initial if reference considered, whether or had citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.